Table 1.
Safety Population Baseline Demographics and Clinical Characteristics
| Pooled Short-Term Studies |
Long-Term Study(n = 874)a,b | |||||
| Characteristic | Desvenlafaxine 50 mg (n = 1,425) | Desvenlafaxine 100 mg (n = 574) | Placebo(n = 1,400) | |||
| Age, y | ||||||
| Mean | 43.7 | 42.2 | 43.3 | 45.0 | ||
| Range | 18–86 | 18–78 | 18–85 | 18–87 | ||
| Sex, n (%) | ||||||
| Female | 981 (68.8) | 366 (63.8) | 953 (68.1) | 608 (69.6) | ||
| Race, n (%) | ||||||
| White | 1,033 (72.5) | 457 (79.6) | 1,001 (71.5) | 729 (83.4) | ||
| Black | 217 (15.2) | 70 (12.2) | 192 (13.7) | 55 (6.3) | ||
| Asian | 132 (9.3) | 12 (2.1) | 139 (9.9) | 9 (1.0) | ||
| Other | 43 (3.0) | 35 (6.1) | 68 (4.9) | 81 (9.3) | ||
| Weight, kg | ||||||
| Mean (SD) | 83.3 (23.3) | 81.7 (21.0) | 81.6 (22.5) | 77.2 (19.5) | ||
| BMI category, n (%)c | ||||||
| Underweight | 37 (2.6) | 13 (2.3) | 36 (2.6) | 24 (2.8) | ||
| Normal | 409 (28.7) | 190 (33.1) | 446 (31.8) | 321 (36.7) | ||
| Overweight | 399 (28.0) | 166 (28.9) | 399 (28.5) | 271 (31.0) | ||
| Obese | 580 (40.7) | 205 (35.7) | 519 (37.1) | 258 (29.5) | ||
| Baseline HDRS-17 total score | ||||||
| Mean (SD) | 23.0 (3.1) | 23.7 (2.6) | 23.1 (3.1) | 24.2 (2.8) | ||
a
Twenty weeks of open-label desvenlafaxine 50 mg/d, followed by 6 months of double-blind desvenlafaxine 50 mg/d or placebo.
b
From open-label baseline.
c
BMI categories: normal = BMI ≤ 25 kg/m2, overweight = 25 kg/m2 < BMI ≤ 30 kg/m2, obese = BMI > 30 kg/m2.
Abbreviations: BMI = body mass index, HDRS-17 = 17-item Hamilton Depression Rating Scale.